MedTrace Logo

Glucose Tolerance Study

NCT07412730 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 19

Last updated 2026-04-28

No results posted yet for this study

Summary

The goal of this clinical trial is to assess whether TRPTI (oleoylethanolamide) can improve glucose tolerance in healthy adults aged 18 years and above with BMI 18.5-29.9 kg/m². The main questions it aims to answer are:

* Does TRPTI improve glucose tolerance as measured by glucose area under the curve (AUC) from 0-120 minutes following a glucose load?
* Does TRPTI reduce peak glucose response and alter the time to peak glucose concentration?
* Are there dose-dependent effects between 150 mg and 300 mg doses of TRPTI?

Researchers will compare TRPTI 150 mg, TRPTI 300 mg, and placebo in a crossover design to see if TRPTI improves glucose metabolism and insulin sensitivity compared to placebo. Participants will complete 3 clinic visits (each lasting approximately 4 hours) with a minimum 6-day washout period between visits.

Conditions

  • Healthy Volunteers
  • Glucose Tolerance

Interventions

DIETARY_SUPPLEMENT

TRPTI 150mg

Single dose of 150mg TRPTI will be orally administered.

DIETARY_SUPPLEMENT

TRPTI 300mg

Single dose of 300mg TRPTI will be orally administered.

OTHER

Placebo

Single dose of placebo will be orally administered.

Sponsors & Collaborators

  • Gencor Pacific Limited, Hong Kong

    collaborator INDUSTRY

  • RDC Clinical Pty Ltd

    lead INDUSTRY

Principal Investigators

  • RV Venkatesh · Gencor Pacific

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-03-11
Primary Completion
2026-04-02
Completion
2026-04-02

Countries

  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07412730 on ClinicalTrials.gov